Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058013 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Neumora Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
- 20
- Study locations
NCT06058013: Recruiting Phase 3 study of Major Depressive Disorder, sponsored by Neumora Therapeutics.
NCT06058013 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Neumora Therapeutics. The registered enrollment target is 332 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06058013, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Neumora Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Primary Outcome
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. Thus, scores in the MADRS range from 0
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NMRA-335140
Study Locations (20)
Florida
- Neumora Investigator Site - Bradenton
- Neumora Investigator Site - Hollywood
- Neumora Investigator Site - Homestead
- Neumora Investigator Site - Lauderhill
- Neumora Investigator Site - Maitland
- Neumora Investigator Sites - Miami
- Neumora Investigator Site - Miami
- Neumora Investigator Site - Miami
- Neumora Investigator Site - Miami
- Neumora Investigator Site - Miami
- Neumora Investigator Site - Miami Lakes
- Neumora Investigator Site - Miami Lakes
- Neumora Investigator Site - Orlando
California
- Neumora Investigator Site - Encino
- Neumora Investigator Site - Garden Grove
- Neumora Investigator Site - Los Alamitos
- Neumora Investigator Site - Newport Beach
- Neumora Investigator Site - Orange
- Neumora Investigator Site - Santa Ana
Connecticut
- Neumora Investigator Site - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What NCT06058013 shows while recruiting
NCT06058013 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06058013 names 20 study sites across 3 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06058013 about?
NCT06058013 is a clinical study titled "Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder". This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatm...
What is the current status of trial NCT06058013?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2023-12-20. Estimated completion is 2026-06.
What conditions does trial NCT06058013 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06058013?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 (DRUG).
Who is sponsoring clinical trial NCT06058013?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06058013 being conducted?
This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06058013's enrollment target sits among peer trials
332 50th of 282 higher than 232 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI